Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression

  • Sandhya Cautha BronxCare Health System, Bronx, NY, USA
  • Sorab Gupta BronxCare Health System, Bronx, NY, USA
  • Ahmad Ahnif BronxCare Health System, Bronx, NY, USA
  • Valentina Morangthem BronxCare Health System, Bronx, NY, USA
  • Kevin Jain BronxCare Health System, Bronx, NY, USA

Keywords

Lymphoplasmacytic lymphoma, non-IgM, Waldenstrom macroglobulinemia, lambda light chains, MYD88 L265P, ibrutinib, rituximab

Abstract

Introduction: Lymphoplasmacytic lymphoma (LPL) is a rare low-grade B-cell neoplasm that accounts for approximately 2% of all haematological malignancies. Most patients have the clinical syndrome of Waldenstrom macroglobulinemia (WM), which is defined as LPL with an associated immunoglobulin M (IgM) serum monoclonal protein. Roughly 5% of LPL patients secrete non-IgM paraproteins (e.g., IgG, IgA, kappa, lambda) or are non-secretory.

Case description: We report the case of a 41-year-old woman who was diagnosed with non-IgM LPL with lambda light chain monoclonal paraprotein production and normal serum immunoglobulin levels. The MYD88 L265P mutation was detected on fluorescence in-situ hybridization (FISH) analysis of the bone marrow. The patient underwent treatment with a combination of ibrutinib and rituximab. There was an initial response but she died 8 months after diagnosis.   

Discussion: Non-IgM LPL poses diagnostic and therapeutic challenges to clinicians as it is an exceptionally rare malignancy with a heterogeneous clinicopathological presentation and scarce literature. Among non-IgM LPL cases, those with lambda light chain production are even more rare. To the best of our knowledge, none have been reported to date. The addition of MYD88 L265P testing to the diagnostic armamentarium of non-IgM LPL cases is advisable for potential therapeutic reasons.

VIEW THE ENTIRE ARTICLE

References

  • Swerdlow S, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France; IARC; 2008.
  • Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016 May 19;127>(20):2375–2390.
  • Castillo JJ, Ghobrial IM, Treon SP. Biology, prognosis, and therapy of Waldenström macroglobulinemia. Cancer Treat Res 2015;165:177–195.
  • Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L, et al. Waldenström macroglobulinemia: review of pathogenesis and management. Clin Lymphoma Myeloma Leuk 2017 May 1;17(5):252–262.
  • Naderi N, Yang DT. Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Arch Pathol Lab Med 2013 Apr;137(4):580–585.
  • Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 2012 Aug 30;367(9):826–833.
  • Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, et al. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma 2016 May 3;57(5):1104–1113.
  • King RL, Gonsalves WI, Ansell SM, Greipp PT, Frederick LA, Viswanatha DS, et al. Lymphoplasmacytic lymphoma with a non-IgM paraprotein shows clinical and pathologic heterogeneity and may harbor MYD88 L265P mutations. Am J Clin Pathol 2016 Jun 1;145(6):843–851.
  • Varettoni M, Boveri E, Zibellini S, Tedeschi A, Candido C, Ferretti VV, et al. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: a multicentric study of the Rete Ematologica Lombarda (REL) network. Am J Hematol 2019;94(11):1193–1199.
  • Kang J, Hong JY, Suh C. Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience. Blood Res 2018 Sep 31;53(3):189–197.
  • Itchaki G, Dubeau T, Keezer A, Meid K, Xu L, Yang G, et al. Non-IgM secreting lymphoplasmacytic lymphoma-experience of a reference center for Waldenstrom macroglobulinemia. Blood 2018 Nov 29;132:2886.
  • Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol 2018 Apr;181(1):77–85.
  • Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol 2018 Aug;97(8):1417–1425.
  • Ito K, Nishiyama R, Hirano K, Yamada K, Sekiguchi N. Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature. Blood Res 2019 Sep 1;54(3):236–240.
  • Castillo JJ, Ghobrial IM, Treon SP. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma 2016 Nov 1;57(11):2699–2701.
  • Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med 2018 Jun 21;378(25):2399–2410.
  • Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, et al. Ibrutinib treatment in Waldenström's macroglobulinemia: follow-up efficacy and safety from the iNNOVATETM study. Blood 2018 Nov 29;132:149.
  • Published: 2022-02-11

    Issue: 2022: Vol 9 No 2 (view)

    Section: Articles

    How to cite:
    1.
    Cautha S, Gupta S, Ahnif A, Morangthem V, Jain K. Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression. EJCRIM 2022;9 doi:10.12890/2022_003106.

    Most read articles by the same author(s)